Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy
- 1 December 1995
- journal article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 25 (6), 457-462
- https://doi.org/10.1002/mpo.2950250607
Abstract
Tropisetron (Navoban®, Sandoz Pharma Ltd., Basel, Switzerland), a selective antagonist of the serotonin receptor (5‐HT3) dosed once‐daily at 0.2 mg/kg (with a maximum of 5 mg daily), was evaluated in the prevention of chemotherapy‐induced nausea and vomiting in 131 children with a median age of 5 years (age 10 weeks to 21 years). Acute lymphocytic leukemia was the most common malignancy (49%). Most children (82%) had received cytotoxic chemotherapy before enrollment. Patients received tropisetron during one or more courses of chemotherapy (455 courses in total). Tropisetron was administered slowly intravenously as a single dose before the start of chemotherapy on day 1 and intravenously or by mouth the subsequent days as a single daily dose (median treatment duration: 5 days). Response to tropisetron per 24 hour period on the first 5 days of each chemotherapy course was graded as complete (absence of both nausea and vomiting), partial (one to four vomits and/or less than 5 hours of nausea), or failure. Overall complete response on day 1 was observed in 305 out of 455 chemotherapy courses (67%). The patients receiving intravenous chemotherapy (N = 92) had a 70% complete response rate and a 26% partial response rate on day 1, both for course 1 and course 2. The percentage of complete responders increased the subsequent days of the course. Emesis after day 1 was observed primarily during courses with the most emetogenic chemotherapy. No side‐effects of tropisetron other than a single case of diarrhoea were documented in this study.Keywords
This publication has 12 references indexed in Scilit:
- Safety, tolerability, efficacy and plasma concentrations of tropisetron after administration at five dose levels to children receiving cancer chemotherapyEuropean Journal Of Cancer, 1994
- Tropiseton (ICS 205–930) in Pediatric OncologyJournal of Pediatric Hematology/Oncology, 1994
- Prevention of emesis by ics 205-930 in children receiving cytotoxic chemotherapyEuropean Journal Of Cancer, 1993
- Compassionate use of tropisetron in patients at high risk of severe emesisAnnals Of Oncology, 1993
- Tropisetron in the control of nausea and vomiting induced by combined cancer chemotherapy in childrenAnnals of Oncology, 1993
- The development of tropisetron in its clinical perspectiveAnnals Of Oncology, 1993
- Antiemetic therapy for chemotherapy-induced vomiting: Metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine aloneThe Journal of Pediatrics, 1989
- Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.Journal of Clinical Oncology, 1985
- Paradoxical effects of prophylactic phenothiazine antiemetics in children receiving chemotherapy.Journal of Clinical Oncology, 1984
- Dystonic Reactions in Children Caused by MetoclopramideArchives of Disease in Childhood, 1970